FDA Submits New Cannabis Products Enforcement Policy For White House Review
The FDA cannabis enforcement policy marks a key regulatory step for the evolving cannabis marketplace. This policy aims to standardize product labeling and safety documentation. Clinicians should monitor this policy for clearer guidance on cannabis…
Pa. Senate Amends Cannabis Bill with Stricter Pennsylvania Hemp Standards
Pennsylvania hemp standards have been updated to align with stricter federal regulations, enhancing cannabis product safety. These changes reduce contamination risks and improve product consistency for medical cannabis users. Clinicians can now counsel…
With Marijuana Rescheduling Still Pending, Federal Workplace Drug Testing Rules Aren’t Changing
Federal workplace drug testing policies marijuana remain unchanged despite ongoing cannabis rescheduling efforts. This creates challenges for clinicians counseling patients on employment risks. Understanding these policies is crucial for navigating the…
U.S. Farm Bill revisions would modestly reshape rules for fiber and grain growers
Farm bill hemp regulations are set to reshape rules for fiber and grain growers. These revisions clarify distinctions between industrial hemp and cannabinoid production. Improved oversight aims to enhance product safety and consistency for patients.
As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
The supreme court medical cannabis case has significant implications for patient legal protections. This case could affect state medical cannabis programs and patient access. Clinicians and patients alike should monitor this evolving legal landscape…
In the Mix: 5 More Articles — March 15, 2026
This article reviews recent cannabis policy developments relevant to clinicians. It highlights regulatory disputes and labor safety issues in the cannabis industry. Understanding these developments is crucial for clinical frameworks addressing cannabis…
New Top Cannabis Regulator Sets Priorities In First Board Meeting
The new cannabis regulatory priorities focus on improving product safety and testing standards. These changes directly affect clinical practice and patient access. Clinicians must stay informed about evolving regulations to guide patients effectively.
Quasi-randomization to Cannabinoid Condition in Studies of US Legal Market Cannabis
Quasi-randomization cannabis studies face unique challenges due to federal Schedule I restrictions that limit true randomization. These studies often involve selection bias, affecting the reliability of cannabis clinical evidence. Understanding these…
This Week in Cannabis: March 13, 2026
This week’s roundup covers marijuana reclassification drug testing impacts and recent clinical cannabis research. Key studies on cannabinoids for insomnia and anxiety highlight mixed outcomes. Regulatory updates and synthetic opioid scheduling also shape…
Marijuana Rescheduling Is A ‘Transitional’ Step That Must Be Followed By Banking Reform
Marijuana rescheduling banking reform is a critical transitional step following federal cannabis rescheduling to Schedule III. This reform will facilitate research and improve financial access for cannabis businesses. Without banking reform, the cannabis…